KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Total Debt (2016 - 2024)

Exact Sciences has reported Total Debt over the past 15 years, most recently at $50.0 million for Q1 2024.

  • Quarterly Total Debt changed 0.0% to $50.0 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $50.0 million through Mar 2024, changed 0.0% year-over-year, with the annual reading at $50.0 million for FY2023, 0.0% changed from the prior year.
  • Total Debt was $50.0 million for Q1 2024 at Exact Sciences, roughly flat from $50.0 million in the prior quarter.
  • Over five years, Total Debt peaked at $50.0 million in Q2 2022 and troughed at $21.4 million in Q3 2021.
  • The 5-year median for Total Debt is $50.0 million (2022), against an average of $38.1 million.
  • Year-over-year, Total Debt plummeted 93.17% in 2020 and then soared 133.23% in 2022.
  • A 5-year view of Total Debt shows it stood at $22.3 million in 2020, then fell by 4.05% to $21.4 million in 2021, then soared by 133.23% to $50.0 million in 2022, then changed by 0.0% to $50.0 million in 2023, then changed by 0.0% to $50.0 million in 2024.
  • Per Business Quant, the three most recent readings for EXAS's Total Debt are $50.0 million (Q1 2024), $50.0 million (Q4 2023), and $50.0 million (Q3 2023).